FANCD2 and neoplasm: FA4 was obtained according to a polypharmacology strategy, following other σ2 receptor-targeting thiosemicarbazones (e.g., MLP44 and PS3) that had shown promising antitumor properties in a panel of immortalized human PDAC cells and in a murine (KP02) tumor model [17,18].